Use of the «Minnesota living with heart failure» quality of life questionnaire in Spain;Aplicación en España del cuestionario sobre calidad de vida «Minnesota Living With Heart Failure» para la insuficiencia cardíca

Revista Espanola de Cardiologia

Volumn 57, Issue 2, 2004, Pages 155-160

  Parajón, Teresa ^a   Lupón, Josep ^a   Gozález, Beatriz ^a   Urrutia, Agustín ^a   Altimir, Salvador ^a   Coll, Ramón ^a   Prats, Montserrat ^a   Valle, Vicente ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

Heart failure; Minnesota; Quality of life

Indexed keywords

ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ADULT; AGE; AGED; ALCOHOLIC CARDIOMYOPATHY; ANEMIA; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DEMOGRAPHY; DIABETES MELLITUS; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MORTALITY; OUTCOMES RESEARCH; QUALITY OF LIFE; SCORING SYSTEM; SEX DIFFERENCE; SPAIN; VALVULAR HEART DISEASE;

EID: 1642526434     PISSN: 03008932     EISSN: None     Source Type: Journal    
DOI: 10.1157/13057266     Document Type: Article

References (31)

1. McMurray JJ, Stewart S. Epidemiology, aetiology, and prognosis of heart failure. Heart 2000;83:596-602.
2. McCullough P, Philbin E, Speretus J, Kaatz S, Sandberg K, Weawer D. Confirmation of a heart failure epidemic: Findings from the Resource Utilisation Among Congestive Heart Failure (REACH) Study. J Am Coll Cardiol 2002;39:60-9.
3. McMurray JJ, Petrie MC, Murdoch DR, Davie AP. Clinical epidemiology of heart failure: Public and private health burden. Eur Heart J 1998;19(Suppl P):9-12.
4. Konstam V, Salem D, Pouleur H, Kostis J, Gorkin L, Shumaker S, et al. Baseline quality of life as a predictor of mortality and hospitalization in 5,025 patients with congestive heart failure. SOLVD Investigations. Studies of Left Ventricular Dysfunction Investigators. Am J Cardiol 1996;78:890-5.
5. Hulsmann M, Berger R, Sturm B, Bojic A, Woloszczuk W, Bergler-Klein J, et al. Prediction of outcome by neurohumoral activation, the six-minute walk test and the Minnesota Living with Heart Failure Questionnaire in an outpatient cohort with congestive heart failure. Eur Heart J 2002;23:886-91.
6. Rogers WJ, Johnstone DE, Yusuf S, Weiner DH, Gallagher P, Bittner VA, et al. Quality of life among 5,025 patients with left ventricular dysfunction randomized between placebo and enalapril: The Studies of Left Ventricular Dysfunction. The SOLVD Investigators. J Am Coll Cardiol 1994;23:393-400.
7. Alta F, Briançon S, Guillemin F, Jullière Y, Mertès PM, Villemot JP, et al, for the EPICAL investigators. Self-rating of quality of live provides additional prognostic information in heart failure. Insights into the EPICAL study. Eur J Heart Failure 2002;4:337-43.
8. Guyatt GH. Measurement of health related quality of life in heart failure. J Am Coll Cardiol 1993;22(Suppl A):185A-91A.
9. Rector TS, Kubo SH, Cohn JN. Patients' self assessment of their congestive heart failure: II. Content, reliability and validity of a new measure-the Minnesota Living with Heart Failure questionnaire. Heart Failure 1987;3:198-209.
10. Rector TS, Kubo SH, Cohn JN. Validity of the Minnesota living with heart failure questionnaire as a measure of therapeutic response to enalapril or placebo. Am J Cardiol 1994;71:1106-7.
11. Rector TS, Cohn JN. Assessment of patient outcome with the Minnesota Living With Heart Failure questionnaire: Reliability and validity during a randomised, double blind, placebo-controlled trial of pimobendan. Am Heart J 1992;124:1017-25.
12. Rector TS, Johnson G, Dunkman B, Daniels B, Farrell L, Smith B, et al. Evaluation by patients with heart failure of effects of enalapril compared with hydralazine plus isosorbide dinitrate on quality of life. V-HeFT II. Circulation 1993;87(Suppl VI):71-7.
13. Kubo S, Gollub S, Bourge R, Rahko P, Cobb F, Jessup M, et al. Beneficial Effects of pimobendan on exercise tolerance and quality of life in patients with heart failure. results of a multicenter trial. Circulation 1992;85:942-9.
14. Briançon S, Alla F, Mejat E, Guillemin F, Villemot JP, Mertès PM, et al. Measurement of functional inability and quality of life in cardiac failure. Transcultural adaptation and validation of the Goldman, Minnesota and Duke questionnaires. Arch Mal Coeur Vaiss 1997;90:1577-85.
15. Quittan M, Wiesinger GF, Crevenna R, Nuhr MJ, Posch M, Hülsman M, et al. Cross-cultural adaptation of the Minnesota Living with Heart failure Questionnaire for german-speaking patients. J Rehabil Med 2001;33:182-6.
16. Stanek E, Oates M, McGhan F, Denofrio D, Loh E. Preferences for treatment outcomes in patients with heart failure: Symptoms versus survival. J Card Failure 2000;3:225-32.
17. Lewis EF, Johnson PA, Johnson W, Collins C, Griffin L, Stevenson LW. Preferences for quality of life or survival expressed by patients with heart failure. J Heart Lung Transplant 2001;20: 1016-24.
18. Wiklund I, Lindvall K, Swedberg K, Zupkis RV. Self-assessment of quality of life in severe heart failure. Scand J Psychol 1987;28:220-5.
19. Guyatt GH, Nogradi S, Halcrow S, Singer J, Sullivan MJ, Fallen EL. Development and testing of a new measure of health status for clinical trials in heart failure. J Gen Intern Med 1989;4:101-7.
20. Green CP, Porter CB, Bresnahan R, Spertus JA. Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: A new health status measure for heart failure. J Am Coll Cardiol 2000;35:1245-55.
21. O'Leary C, Jones P. The left ventricular dysfunction questionnaire (LVD-36): Reliability, validity and responsiveness. Heart 2000;83:634-40.
22. Feinstein A, Fisher M, Pigeon G. Changes in dyspnoea-fatigue rating as indicators of quality of life in the treatment of congestive heart failure. Am J Cardiol 1989;64:50-5.
23. Riegel B, Moser DK, Glaser D, Carlson B, Deaton C, Armola R, et al. The Minnesota Living With Heart Failure Questionnaire: Sensitivity to differences and responsiveness to intervention intensity in a clinical population. Nurs Res 2002;51:209-18.
24. Dracup K, Walden JA, Stevenson LW, Brecht ML. Quality of life in patients with advanced heart failure. J Heart Lung Transplant 1992;11:273-9.
25. Riedinger MS, Dracup KA, Brecht ML, Padilla G, Sarna L, Ganz PA. Quality of life in patients with heart failure: Do gender differences exist? Heart Lung 2001;30:105-16.
26. Evangelista S, Kagawa-Singer M, Dracup K. Gender differences in health perceptions and meaning in persons living with heart failure. Heart Lung 2001;30:167-76.
27. Riegel B, Moser DK, Carlson B, Deaton C, Armola R, Sethares K, et al. Gender differences in quality of life are minimal in patients with heart failure. J Cardiac Failure 2003;9:42-8.
28. Lader E, Egan D, Hunsberger S, Garg R, Czajkowski S, McSherry. The effect of digoxin on the quality of life in patients with heart failure. J Cardiac Failure 2003;9:4-12.
29. Kukin M, Kalman J, Charney RH, Levy DK Buchholz-Varley C, Ocampo OF, et al. Prospective, randomized comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure. Circulation 1999;99:2645-51.
30. Reddy P, Dunn AB. The effect of beta-blokers on health-related quality of life in patients with heart failure. Pharmacotherapy 2000;20:679-89.
31. Hutcheon SD, Gillespie ND, Crombie IK, Struthers AD, McMurdo MET. Perindopril improves six minute walking distance in older patients with left ventricular systolic dysfunction: A randomised double blind placebo controlled trial. Heart 2002;88:373-7.